Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides …
2 days ago · Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively. More than 3,500 unique prescribers and over 16,000 prescriptions ...
Verona says COPD drug is off to a flying start | pharmaphorum
2 days ago · Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare professionals prescribing the drug, accounting for around 45% of the ...
Verona Pharma Announces US FDA Approval of Ohtuvayre™ …
Jun 26, 2024 · Ohtuvayre is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment.
Verona's new COPD drug Ohtuvayre racked up sales of $42M in …
2 days ago · Verona charges $2,950 for a monthly dose of Ohtuvayre. The $35,400 annual price exceeds the cost-effectiveness threshold (PDF) of between $7,500 and $12,700 per year established by the Institute ...
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides
2 days ago · Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively. More than 3,500 unique prescribers and over 16,000 prescriptions ...
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE …
Sep 30, 2024 · Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ohtuvayre met the primary endpoint in both ENHANCE-1 and ENHANCE-2, demonstrating statistically significant and clinically meaningful improvements in lung function.
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre …
JUPITER, Fla., June 27, 2024 -- (BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc has received approval from the U.S. Food and...
Verona Pharma Reports Approximately $36 Million in Q4 2024 …
2 days ago · Verona Pharma reports $36M in Q4 and $42M in 2024 sales for Ohtuvayre, with over 16,000 prescriptions filled. Quiver AI Summary. Verona Pharma plc has announced its preliminary unaudited net ...
Verona Pharma Drug With Dual Mechanism Lands FDA ... - MedCity News
Jun 27, 2024 · Verona Pharma’s COPD drug Ohtuvayre is a single small molecule that blocks two targets to bring patients both bronchodilation and anti-inflammatory effects. Verona executives contend their...
Verona scores FDA approval for Ohtuvayre as COPD …
Jun 27, 2024 · The US Food and Drug Administration (FDA) has approved Verona Pharma’s Ohtuvayre (ensifentrine) as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adult patients.
- Some results have been removed